Benralizumab reduces blood basophil percentage and activation without eliciting degranulation 

Victoria del Pozo from the Universidad Autónoma de Madrid, Spain, presents their research findings published in Allergy:
Gil-Martínez, M., et al. (2024), Benralizumab reduces blood basophil percentage and activation in vitro without eliciting degranulation. Allergy. doi.org/10.111...
Follow Allergy on:
Facebook: / eaaciallergy
Twitter: / allergyeaaci
LinkedIn: / allergy-eaaci
Instagram: / allergy.eaaci
Like, share and comment on our videos, thank you.
journalallergy...